Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Norway

Research and Innovation Action · Running

PRIME-ROSE PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials

Coordinator
Oslo Universitetssykehus Hf, Norway
Runs
1 July 2023 to 30 June 2028
Status
Running
EU funding
€6.0m
Total cost
€6.0m
Partners
28 organisations in 19 countries
Type
Research and Innovation Action
Grant agreement
101104269

What the project is doing

In the project's own words, from its summary on CORDIS.

Millions of people in the EU are negatively affected by cancer, and cancer is one of the leading causes of death and morbidity in Europe (ecis.jrc.europa.eu). The PRIME-ROSE consortium will contribute to the Mission Cancer goal to optimise treatment and support quality of life of more than 3 million people by 2030.The PRIME-ROSE consortium envisions to support Mission Cancer through the following objectives: 1) increase access to optimised and affordable treatment interventions for cancer patients that prolong life and increase quality of life, 2) generate clinical evidence and evaluate effectiveness in Precision Cancer Medicine (PCM)-relevant and synthetically randomised, controlled academic investigator-initiated pragmatic clinical trials, and 3) work together across Europe with relevant experts to implement evidence-based PCM in routine practice and address inequalities in access.

This consortium builds on the truly bottom-up, clinician-initiated family of DRUP-like innovative trials that provide broad access to precision medicine for cancer patients. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.

Topics

Who is involved

OrganisationCityCountryRole
Oslo Universitetssykehus HfOsloNorwayCoordinator
Masarykuv Onkologicky UstavBrnoCzechiaAssociatedpartner
Universitatsklinikum HeidelbergHeidelbergGermanyAssociatedpartner
Region HovedstadenHillerodDenmarkParticipant
Sihtasutus Tartu Ulikooli KliinikumTartuEstoniaAssociatedpartner
Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio)BarcelonaSpainAssociatedpartner
Hus-YhtymaHelsinkiFinlandParticipant
Centre De Lutte Contre Le Cancer Leon BerardLyonFranceParticipant
Klinicki Bolnicki Centar SplitSplitCroatiaAssociatedpartner
Orszagos Onkologiai IntezetBudapestHungaryAssociatedpartner
The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near DublinDublinIrelandAssociatedpartner
Istituto Europeo Di Oncologia SRLMilanoItalyAssociatedpartner
Nacionalinis Vezio InstitutasVilniusLithuaniaAssociatedpartner
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek ZiekenhuisAmsterdamNetherlandsParticipant
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsAssociatedpartner
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie -Panstwowy Instytut BadawczyWarszawaPolandAssociatedpartner
Instituto Portugues De Oncologia Do Porto Francisco Gentil, EpePortoPortugalParticipant
Asociatia Centrul Pentru Inovatie in MedicinaBucharestRomaniaAssociatedpartner
Centrul De Oncologie Sf Nectarie SRLCraiovaRomaniaAssociatedpartner
Ihe, Institutet for Halso- Och Sjukvardsekonomi AktiebolagLundSwedenParticipant
Karolinska InstitutetStockholmSwedenAssociatedpartner
Region SkaneKristianstadSwedenAssociatedpartner
Region UppsalaUppsalaSwedenParticipant
Stiftelsen Stockholm School of Economics (sse) Institute for ResearchStockholmSwedenParticipant
Vastra GotalandsregionenVanersborgSwedenAssociatedpartner
Cancer Research UK LbgLondonUnited KingdomAssociatedpartner
The University of ManchesterManchesterUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI